Todays Report: The Barrington Research Equities Analysts Increase Earnings Estimates for Anika Therapeutics Inc. (ANIK)

The Barrington Research Equities Analysts Increase Earnings Estimates for Anika Therapeutics Inc. (ANIK)

Anika Therapeutics Inc. (NASDAQ:ANIK) – Investment analysts at Barrington Research raised their FY2016 earnings per share estimates for shares of Anika Therapeutics in a research note issued on Friday. Barrington Research analyst M. Petusky now expects that the firm will earn $2.15 per share for the year, up from their prior estimate of $1.95. Barrington Research also issued estimates for Anika Therapeutics’ Q4 2016 earnings at $0.53 EPS, Q1 2017 earnings at $0.42 EPS, Q3 2017 earnings at $0.51 EPS, Q4 2017 earnings at $0.74 EPS, FY2017 earnings at $2.22 EPS and FY2018 earnings at $2.15 EPS.

Separately, Zacks Investment Research cut shares of Anika Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 11th.

Anika Therapeutics (NASDAQ:ANIK) opened at 43.00 on Monday. The firm has a market capitalization of $628.79 million, a price-to-earnings ratio of 18.45 and a beta of 1.49. The stock has a 50 day moving average of $46.12 and a 200 day moving average of $48.02. Anika Therapeutics has a one year low of $35.07 and a one year high of $54.96.

Anika Therapeutics (NASDAQ:ANIK) last issued its quarterly earnings data on Wednesday, October 26th. The company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.47 by $0.12. Anika Therapeutics had a net margin of 33.64% and a return on equity of 17.21%. The firm had revenue of $25.79 million for the quarter, compared to analyst estimates of $26.60 million. During the same period in the prior year, the business posted $0.55 EPS. The business’s revenue for the quarter was up 8.9% compared to the same quarter last year.

A number of institutional investors have recently bought and sold shares of ANIK. BlackRock Inc. increased its position in Anika Therapeutics by 99.0% in the second quarter. BlackRock Inc. now owns 2,032 shares of the company’s stock valued at $109,000 after buying an additional 1,011 shares during the period. Teacher Retirement System of Texas increased its position in Anika Therapeutics by 14.1% in the second quarter. Teacher Retirement System of Texas now owns 2,037 shares of the company’s stock valued at $109,000 after buying an additional 252 shares during the period. Mason Street Advisors LLC acquired a new position in Anika Therapeutics during the second quarter valued at $150,000. Paloma Partners Management Co acquired a new position in Anika Therapeutics during the second quarter valued at $233,000. Finally, AHL Partners LLP acquired a new position in Anika Therapeutics during the second quarter valued at $247,000. Hedge funds and other institutional investors own 74.50% of the company’s stock.

Anika Therapeutics Company Profile

Related posts

Leave a Comment